Anokion is a leading immune tolerance company advancing novel, antigen-specific treatments for people living with the devastating effects of autoimmune disease. Anokion is strategically progressing its development pipeline based on an industry-leading, novel platform that harnesses the body’s natural tolerance pathways. Initially formed as a spin-off from the Ecole Polytechnique Fédérale de Lausanne (EPFL), the company is funded by leading investors, including Versant Ventures, Novo Ventures, and Novartis Venture Fund.
Topas Therapeutics (Hamburg, Germany) is focused on developing products in areas of major unmet need, including autoimmune diseases, allergies and anti-drug antibodies. Topas’ technology induces antigen-specific regulatory T cells in the liver by mimicking bloodborne antigens via the Company´s proprietary peptide-loaded nanoparticles. Topas has programs in MS, T1D and an orphan indication, which is planned to enter the clinic in 2019. The Company has collaborations with Eli Lilly and Company and with Evotec.
Orion BioScience Inc. is an preclinical stage biotechnology company focused on developing our “Soluble Antigen Array’ (or SAgA) technology to intercept and prevent the onset of autoimmune diseases in at risk and early stage patients. Our research into treating multiple sclerosis, neuromyelitis optica, and type-1 diabetes has shown that Orion can develop disease specific immunotherapeutics that can re-tolerize and restore the healthy immune state. The Orion team leverages extensive development experience, and strong clinical relationships, to rapidly progress first-in-class, blockbuster treatments for NMO and T1D into the clinic.
Nektar Therapeutics is a research-based development stage biopharmaceutical company whose mission is to discover and develop innovative medicines to address the unmet medical needs of patients. Our R&D pipeline of new investigational medicines includes treatments for cancer, autoimmune disease and chronic pain. We leverage Nektar’s proprietary and proven chemistry platform in the discovery and design of our new therapeutic candidates.
Selecta Biosciences, Inc. is a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance technology (ImmTOR) platform. Selecta plans to combine ImmTOR with a range of biologic therapies for rare and serious diseases that require new treatment options due to high immunogenicity. The company’s current proprietary pipeline includes ImmTOR-powered therapeutic enzyme and gene therapy product candidates.